Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescent analysis of BMPR1A /CD292 was performed using 70% confluent log phase SH-SY5Y cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with BMPR1A /CD292 Rabbit Polyclonal Antibody (38-6000) at 2ug/ml in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (A27034) a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing cytoplasmic localization. Panel e shows the no primary antibody control. The images were captured at 60X magnification.
|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide derived from an internal region of the human BMPR-1A (bone morphogenetic protein receptor type 1A, Serine/threonine protein kinase receptor R5 (SKR5), activin receptor-like kinase-3 (ALK-3)), which differs from mouse and rat BMPR-1A by one nonconservative amino acid replacement.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.4|
|Contains||0.1% sodium azide|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||3-5 µg/10^6 cells|
|Immunocytochemistry (ICC)||2 µg/mL|
|Immunofluorescence (IF)||2 µg/mL|
|Immunoprecipitation (IP)||Assay Dependent|
|Western Blot (WB)||2 µg/mL|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. BMPRIA binds BMP4 with high-affinity in solution and is a potent BMP-4 antagonist in vitro. In adult tissues, BMPRIA is widely expressed, with the highest expression levels detected in skeletal muscle. BMPRIA is also widely expressed during embryogenesis.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
10q23del; activin A receptor; activin A receptor, type II-like kinase 3; Activin receptor-like kinase 3; ACVRLK3; ALK-3; ALK3; BMP type-1A receptor; BMP-2/BMP-4 receptor; BMPR-1A; BMPRIA; Bone morphogenetic protein 4 receptor; bone morphogenetic protein receptor type IA; Bone morphogenetic protein receptor type-1A; bone morphogenetic protein receptor, type 1A; bone morphogenetic protein receptor, type IA; CD292; Serine/threonine-protein kinase receptor R5; SKR5; type II-like kinase 3
10q23del; 1110037I22Rik; ACVRLK3; ALK3; AU045487; Bmpr; BMPR-IA; BMPR1A; CD292; SKR5